Hyperphosphatemic familial tumoral calcinosis: Response to acetazolamide and postulated mechanisms

Gal Finer, Heather E. Price, Richard M. Shore, Kenneth White, Craig B. Langman

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Hyperphosphatemic familial tumoral calcinosis (HFTC) is characterized by enhanced renal phosphate absorption, hyperphosphatemia, and tumor-like extraosseous calcifications due to inactivating mutations in FGF23 or associated proteins. Surgical excision is needed when low phosphate diet and phosphate binders are ineffective. Sporadic reports have supported acetazolamide use. We report on a 7-year-old African American boy who presented with severe HFTC requiring numerous surgical excisions. Tumors continued to appear and others reoccurred despite phosphate restriction and sevelamer carbonate. At the age of 9.5 years, acetazolamide (40mg/kg/day) was added and resulted in mild metabolic acidosis (bicarbonate 25.3mEq/L vs. 21.4mEq/L, P<0.001; serum pH 7.38 vs. 7.31, P=0.013, pre- and post-acetazolamide, respectively) but no change in tubular reabsorption of phosphate (TRP) (96.9% vs. 95.9%, P=0.34) or serum phosphate (6.6mg/dl vs. 6.9mg/dl, P=0.52 pre- and post-acetazolamide, respectively). Following the initiation of acetazolamide therapy, the patient experienced significant improvement in disease course as indicated by resolution of localized bone pain, cessation of tumor formation, and no tumor recurrence. Despite mild metabolic acidosis, our patient had improved linear growth and did not develop any other side effects related to therapy. Intact FGF23 remained abnormally low throughout disease course, while C-terminal FGF23 increased with acetazolamide. We conclude that acetazolamide can control severe HFTC by inducing mild metabolic acidosis despite no change in serum phosphate or TRP. This effect may be exerted though improved calcium-phosphate complex solubility and increased FGF23 locally.

Original languageEnglish
Pages (from-to)1545-1549
Number of pages5
JournalAmerican Journal of Medical Genetics, Part A
Volume164
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Acetazolamide
Phosphates
Acidosis
Neoplasms
Serum
Hyperphosphatemia
Hyperphosphatemic Familial Tumoral Calcinosis
Bicarbonates
African Americans
Solubility
Diet
Bone and Bones
Recurrence
Pain
Mutation

Keywords

  • Acetazolamide
  • Calcifications
  • Calcium-phosphate solubility
  • FGF23
  • GALNT3
  • Hyperphosphatemia
  • Hyperphosphatemic familial tumoral calcinosis
  • Metabolic acidosis

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

Hyperphosphatemic familial tumoral calcinosis : Response to acetazolamide and postulated mechanisms. / Finer, Gal; Price, Heather E.; Shore, Richard M.; White, Kenneth; Langman, Craig B.

In: American Journal of Medical Genetics, Part A, Vol. 164, No. 6, 2014, p. 1545-1549.

Research output: Contribution to journalArticle

Finer, Gal ; Price, Heather E. ; Shore, Richard M. ; White, Kenneth ; Langman, Craig B. / Hyperphosphatemic familial tumoral calcinosis : Response to acetazolamide and postulated mechanisms. In: American Journal of Medical Genetics, Part A. 2014 ; Vol. 164, No. 6. pp. 1545-1549.
@article{bb9987621daf497a8626de113b4b2e42,
title = "Hyperphosphatemic familial tumoral calcinosis: Response to acetazolamide and postulated mechanisms",
abstract = "Hyperphosphatemic familial tumoral calcinosis (HFTC) is characterized by enhanced renal phosphate absorption, hyperphosphatemia, and tumor-like extraosseous calcifications due to inactivating mutations in FGF23 or associated proteins. Surgical excision is needed when low phosphate diet and phosphate binders are ineffective. Sporadic reports have supported acetazolamide use. We report on a 7-year-old African American boy who presented with severe HFTC requiring numerous surgical excisions. Tumors continued to appear and others reoccurred despite phosphate restriction and sevelamer carbonate. At the age of 9.5 years, acetazolamide (40mg/kg/day) was added and resulted in mild metabolic acidosis (bicarbonate 25.3mEq/L vs. 21.4mEq/L, P<0.001; serum pH 7.38 vs. 7.31, P=0.013, pre- and post-acetazolamide, respectively) but no change in tubular reabsorption of phosphate (TRP) (96.9{\%} vs. 95.9{\%}, P=0.34) or serum phosphate (6.6mg/dl vs. 6.9mg/dl, P=0.52 pre- and post-acetazolamide, respectively). Following the initiation of acetazolamide therapy, the patient experienced significant improvement in disease course as indicated by resolution of localized bone pain, cessation of tumor formation, and no tumor recurrence. Despite mild metabolic acidosis, our patient had improved linear growth and did not develop any other side effects related to therapy. Intact FGF23 remained abnormally low throughout disease course, while C-terminal FGF23 increased with acetazolamide. We conclude that acetazolamide can control severe HFTC by inducing mild metabolic acidosis despite no change in serum phosphate or TRP. This effect may be exerted though improved calcium-phosphate complex solubility and increased FGF23 locally.",
keywords = "Acetazolamide, Calcifications, Calcium-phosphate solubility, FGF23, GALNT3, Hyperphosphatemia, Hyperphosphatemic familial tumoral calcinosis, Metabolic acidosis",
author = "Gal Finer and Price, {Heather E.} and Shore, {Richard M.} and Kenneth White and Langman, {Craig B.}",
year = "2014",
doi = "10.1002/ajmg.a.36476",
language = "English",
volume = "164",
pages = "1545--1549",
journal = "American Journal of Medical Genetics, Part C: Seminars in Medical Genetics",
issn = "1552-4825",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Hyperphosphatemic familial tumoral calcinosis

T2 - Response to acetazolamide and postulated mechanisms

AU - Finer, Gal

AU - Price, Heather E.

AU - Shore, Richard M.

AU - White, Kenneth

AU - Langman, Craig B.

PY - 2014

Y1 - 2014

N2 - Hyperphosphatemic familial tumoral calcinosis (HFTC) is characterized by enhanced renal phosphate absorption, hyperphosphatemia, and tumor-like extraosseous calcifications due to inactivating mutations in FGF23 or associated proteins. Surgical excision is needed when low phosphate diet and phosphate binders are ineffective. Sporadic reports have supported acetazolamide use. We report on a 7-year-old African American boy who presented with severe HFTC requiring numerous surgical excisions. Tumors continued to appear and others reoccurred despite phosphate restriction and sevelamer carbonate. At the age of 9.5 years, acetazolamide (40mg/kg/day) was added and resulted in mild metabolic acidosis (bicarbonate 25.3mEq/L vs. 21.4mEq/L, P<0.001; serum pH 7.38 vs. 7.31, P=0.013, pre- and post-acetazolamide, respectively) but no change in tubular reabsorption of phosphate (TRP) (96.9% vs. 95.9%, P=0.34) or serum phosphate (6.6mg/dl vs. 6.9mg/dl, P=0.52 pre- and post-acetazolamide, respectively). Following the initiation of acetazolamide therapy, the patient experienced significant improvement in disease course as indicated by resolution of localized bone pain, cessation of tumor formation, and no tumor recurrence. Despite mild metabolic acidosis, our patient had improved linear growth and did not develop any other side effects related to therapy. Intact FGF23 remained abnormally low throughout disease course, while C-terminal FGF23 increased with acetazolamide. We conclude that acetazolamide can control severe HFTC by inducing mild metabolic acidosis despite no change in serum phosphate or TRP. This effect may be exerted though improved calcium-phosphate complex solubility and increased FGF23 locally.

AB - Hyperphosphatemic familial tumoral calcinosis (HFTC) is characterized by enhanced renal phosphate absorption, hyperphosphatemia, and tumor-like extraosseous calcifications due to inactivating mutations in FGF23 or associated proteins. Surgical excision is needed when low phosphate diet and phosphate binders are ineffective. Sporadic reports have supported acetazolamide use. We report on a 7-year-old African American boy who presented with severe HFTC requiring numerous surgical excisions. Tumors continued to appear and others reoccurred despite phosphate restriction and sevelamer carbonate. At the age of 9.5 years, acetazolamide (40mg/kg/day) was added and resulted in mild metabolic acidosis (bicarbonate 25.3mEq/L vs. 21.4mEq/L, P<0.001; serum pH 7.38 vs. 7.31, P=0.013, pre- and post-acetazolamide, respectively) but no change in tubular reabsorption of phosphate (TRP) (96.9% vs. 95.9%, P=0.34) or serum phosphate (6.6mg/dl vs. 6.9mg/dl, P=0.52 pre- and post-acetazolamide, respectively). Following the initiation of acetazolamide therapy, the patient experienced significant improvement in disease course as indicated by resolution of localized bone pain, cessation of tumor formation, and no tumor recurrence. Despite mild metabolic acidosis, our patient had improved linear growth and did not develop any other side effects related to therapy. Intact FGF23 remained abnormally low throughout disease course, while C-terminal FGF23 increased with acetazolamide. We conclude that acetazolamide can control severe HFTC by inducing mild metabolic acidosis despite no change in serum phosphate or TRP. This effect may be exerted though improved calcium-phosphate complex solubility and increased FGF23 locally.

KW - Acetazolamide

KW - Calcifications

KW - Calcium-phosphate solubility

KW - FGF23

KW - GALNT3

KW - Hyperphosphatemia

KW - Hyperphosphatemic familial tumoral calcinosis

KW - Metabolic acidosis

UR - http://www.scopus.com/inward/record.url?scp=84899980960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899980960&partnerID=8YFLogxK

U2 - 10.1002/ajmg.a.36476

DO - 10.1002/ajmg.a.36476

M3 - Article

C2 - 24668887

AN - SCOPUS:84899980960

VL - 164

SP - 1545

EP - 1549

JO - American Journal of Medical Genetics, Part C: Seminars in Medical Genetics

JF - American Journal of Medical Genetics, Part C: Seminars in Medical Genetics

SN - 1552-4825

IS - 6

ER -